Characteristic | n = 28 (%) | Mean (range) |
Age (y) | 56 (33–90) | |
Histology | ||
Ductal | 18 (64%) | |
Lobular | 4 (14%) | |
Mixed or unknown | 6 (21%) | |
Receptor status | ||
Estrogen receptor–positive | 24 (86%) | |
Progesterone receptor–positive | 21 (75%) | |
Human epidermal growth factor receptor 2–negative | 20 (70%) | |
Dominant lesion type | ||
Lytic | 11 (39%) | |
Sclerotic | 7 (25%) | |
Mixed | 8 (29%) | |
Unknown | 2 (7%) | |
Bone lesions per patient | ||
1–5 | 11 (39%) | |
6–10 | 3 (11%) | |
>10 | 14 (50%) | |
Prior therapy | ||
Chemotherapy | 15 (54%) | |
Endocrine therapy | 17 (61%) | |
Radiation | 13 (46%) | |
No. of prior therapies before enrollment | 2.7 (0–8) | |
On study therapy* | ||
Chemotherapy | 11 (39%) | |
Endocrine therapy | 17 (61%) | |
Time from diagnosis to metastatic diagnosis | 71.8 mo (0–440.3) | |
Time from metastatic diagnosis to enrollment | 18.3 mo (0–71.4) |
↵* Biologic therapy (trastuzumab) was given with chemotherapy or endocrine therapy for patients with human epidermal growth factor receptor 2–positive disease.